Soleno Therapeutics, Inc.
SLNO
$52.94
$0.010.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 94.60M | 91.73M | 66.02M | 32.66M | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 94.60M | 91.73M | 66.02M | 32.66M | -- |
| Cost of Revenue | 1.20M | 863.00K | 1.14M | 696.00K | -- |
| Gross Profit | 93.41M | 90.87M | 64.88M | 31.96M | -- |
| SG&A Expenses | 50.37M | 40.88M | 33.75M | 28.24M | 29.26M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 62.84M | 51.30M | 43.30M | 38.08M | 42.78M |
| Operating Income | 31.76M | 40.43M | 22.72M | -5.42M | -42.78M |
| Income Before Tax | 34.91M | 43.36M | 26.01M | -4.71M | -43.77M |
| Income Tax Expenses | 3.54M | -- | -- | -- | -- |
| Earnings from Continuing Operations | 31.38M | 43.36M | 26.01M | -4.71M | -43.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 31.38M | 43.36M | 26.01M | -4.71M | -43.77M |
| EBIT | 31.76M | 40.43M | 22.72M | -5.42M | -42.78M |
| EBITDA | 32.28M | 40.94M | 23.22M | -4.92M | -42.27M |
| EPS Basic | 0.60 | 0.81 | 0.49 | -0.09 | -0.95 |
| Normalized Basic EPS | 0.42 | 0.52 | 0.31 | -0.04 | -0.55 |
| EPS Diluted | 0.59 | 0.79 | 0.47 | -0.09 | -0.95 |
| Normalized Diluted EPS | 0.42 | 0.51 | 0.30 | -0.04 | -0.55 |
| Average Basic Shares Outstanding | 52.09M | 53.18M | 53.33M | 50.48M | 46.18M |
| Average Diluted Shares Outstanding | 53.07M | 54.33M | 54.92M | 50.48M | 46.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |